Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITK | Q08881 | 17/20 | 0.48 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.44 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.40 |
| ▸ | CLK2 | P49760 | 1/20 | 0.40 |
| ▸ | CLK3 | P49761 | 1/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22685987 | 1.00 | ITK (0.48) | ITKCHEK1FGFR1CLK2CLK3 | |
| SCHEMBL22685974 | 1.00 | ITK (0.48) | ITKCHEK1FGFR1CLK2CLK3 | |
| SCHEMBL22685970 | 0.86 | ITK (0.54) | ITKCHEK1FGFR1 | |
| SCHEMBL22685950 | 0.86 | ITK (0.54) | ITKCHEK1FGFR1 | |
| SCHEMBL22685949 | 0.86 | ITK (0.54) | ITKCHEK1FGFR1 | |
| SCHEMBL22686006 | 0.84 | ITK (0.49) | ITKFGFR1 | |
| SCHEMBL22685939 | 0.84 | ITK (0.49) | ITKFGFR1 | |
| SCHEMBL22685938 | 0.84 | ITK (0.49) | ITKFGFR1 | |
| SCHEMBL22685988 | 0.83 | ITK (0.51) | ITKFGFR1 | |
| SCHEMBL22685986 | 0.83 | ITK (0.51) | ITKFGFR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11396505-B2 | Inhibitors of CaMKK2 and uses of same | NEW YORK UNIVERSITY (US) | 2022-07-26 | — | — | US | disclosed |
| US-11396505-B2 | Inhibitors of CaMKK2 and uses of same | NEW YORK UNIVERSITY (US) | 2022-07-26 | — | — | US | disclosed |
| US-20200369656-A1 | INHIBITORS OF CAMKK2 AND USES OF SAME | NEW YORK UNIVERSITY | 2020-11-26 | — | — | US | disclosed |
| US-20200369656-A1 | INHIBITORS OF CAMKK2 AND USES OF SAME | NEW YORK UNIVERSITY | 2020-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11396505-B2 | Inhibitors of CaMKK2 and uses of same | CAMKK2, CAMKK1, CAMK1 | ITK 636/4885CHEK1 334/4885FGFR1 3980/4885 |
| US-20200369656-A1 | INHIBITORS OF CAMKK2 AND USES OF SAME | CAMKK2, CAMKK1, CAMK1 | ITK 636/4885CHEK1 334/4885FGFR1 3980/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.